Basic research in the context of the development of medical substances and technologies

Authors

  • L. V. Kuznetsova A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
  • L. Yu. Bakhtina Institute of General Pathology and Pathophysiology, Moscow, Russia
  • I. Yu. Malyshev A.I.Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia; Institute of General pathology and Pathophysiology, Moscow, Russia http://orcid.org/0000-0002-2381-9612

DOI:

https://doi.org/10.25557/2310-0435.2018.03.84-86

Keywords:

pharmaceutical company, drugs, cost, development

Abstract

This brief review discusses challenges of pharmaceutical companies and issues of the most rational relationship between the speed, cost, and quality of the process for drug and technology development (DTD). It was concluded that the experimental design and methods of medical and pharmacological research should be developed on the basis of modern principles and ideas about the essence of DTD stages with a particular emphasis on the high quality of scientific research at the stage of discovery.

Downloads

Published

2018-12-28

Issue

Vol. 16 No. 3 (2018): Pathogenesis

Section

Brief reports

How to Cite

Basic research in the context of the development of medical substances and technologies. (2018). Patogenez (Pathogenesis), 16(3), 84-86. https://doi.org/10.25557/2310-0435.2018.03.84-86

Most read articles by the same author(s)

1 2 > >>